Humanigen, Inc. (HGEN)

Market Cap	22.96M
Revenue (ttm)	3.33M
Net Income (ttm)	-108.66M
Shares Out	119.08M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	9.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,590,635
Open	0.193
Previous Close	0.184
Day's Range	0.190 - 0.205
52-Week Range	0.090 - 4.110
Beta	-1.01
Analysts	Sell
Price Target	3.28 (+1,601.25%)
Earnings Date	Feb 27, 2023

About HGEN

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-tar...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2013
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: HGEN

Financial Performance

In 2021, Humanigen's revenue was $3.60 million, an increase of 1052.24% compared to the previous year's $312,000. Losses were -$236.65 million, 164.3% more than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for HGEN stock is "Sell." The 12-month stock price forecast is $3.28, which is an increase of 1,601.25% from the latest price.

Price Target

$3.28

(1,601.25% upside)

Analyst Consensus: Sell